Radioactive drug targets Hard-to-Treat cancers in early trial

NCT ID NCT07232407

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new radioactive drug, lutetium BL-ARC001, in 22 people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage. Participants receive the drug by IV every 6 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium [177Lu] BL-ARC001 (a radioactive drug given by IV infusion)
What this could lead to: If it works, this could lead to a new targeted treatment option for advanced gastrointestinal and other solid tumors.
What could go wrong: This is a very early Phase I trial with only 22 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm Digestive System Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL TUMORS SOLID TUMORS

Contacts and locations

Locations

Sichuan Cancer Hospital
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.